an investment community with a special focus on updating investors with recent news on the U.S. stock market about the small and penny stocks, issues news alert on Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Celldex Therapeutics, Inc. (NASDAQ …
Market News Call · 2/25/2015
It's got to be (once again) irritating for owners of VVUS and ARNA, who have now essentially watched OREX ... Their patience was rewarded today with a breakout from the stock that puts it within reach of moving past a HUGE technical ceiling.
Smallcap Network · ByJames E. Brumley · 3/27/2015
It represents almost all the qualities I look for in a stock in this kind of market. First, I like the stocks of companies that are tied into long-term trends and whose share prices are poised to benefit from multiple catalysts.
Money Morning · 4/10/2012
OREX has seen an appreciation of over 70% in the last 30 days, and VVUS stock has appreciated nearly 10% in the last 5 days. The negative earnings of these three companies are reflected in their negative PEG ratios; ARNA at -1.14, VVUS at -1.63 ...
Following the approval of weight control management drug Belviq by the Food and Drug Administration in 2012, Arena Pharmaceuticals (NASDAQ: ARNA) was expected to be ... raised nearly $101 million from a common stock sales in the first quarter, so its ...
Investopedia · 4/2/2015
Arena Pharmaceuticals' ($ARNA) stock jumped this morning after the market got wind of FDA briefing documents that drilled into the risks and benefits of the company's highly watched weight-drug lorcaserin. The agency is urging its advisers to probe the ...
Fierce Biotech · ByRyan Mcbride · 5/8/2012
An updated list of biotech and pharmaceutical companies that have pending FDA drug approval decisions ... 21.64 million shares making it the most volume active stock in Biotechnology industry. ARNA has current ratio of 7.44 and its total debt-to-equity ...
Property Mentor Group · 7/24/2012
The stock is trading below its 50-day and 200-day moving averages of $4.46 and $4.32, respectively. Moreover, shares of Arena Pharmaceuticals Inc. have an RSI of 45.30. The complete research on ARNA is available for free at: http://get.Investor-Edge.
Market Watch · 5/18/2015
ObesityWeekSM 2013 is taking place November 11-16 in Atlanta, Georgia. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)’s stock on Nov 15, 2013 reported an increase of 6.83% to the closing price of $5.46. Its fifty two weeks range was $4.05 – $11.00. · 11/18/2013
A year ago, they were trading at $4.33. This story was generated by Automated Insights ( using data from Zacks Investment Research. Access a Zacks stock report on ARNA at
The Huffington Post · 8/5/2015